tiprankstipranks
CareDx Reports Strong Q3 2024 Revenue Growth
Company Announcements

CareDx Reports Strong Q3 2024 Revenue Growth

CareDx ( (CDNA) ) has provided an announcement.

Don't Miss our Black Friday Offers:

CareDx, Inc., a leader in precision medicine for transplant patients, has announced its preliminary financial results for Q3 2024, highlighting a strong performance with an expected revenue increase of 23% year-over-year, reaching $82-$83 million. The company saw significant growth in testing services and patient solutions, resulting in a remarkable 16% rise in testing volume. With cash reserves of approximately $240 million and no debt, CareDx is well-positioned for future growth, as it prepares for the official earnings release on November 4, 2024.

For an in-depth examination of CDNA stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyCareDx management to meet with Craig Hallum
TheFlyCareDx price target lowered to $35 from $40 at BTIG
TipRanks Auto-Generated NewsdeskCareDx Inc. Reports Solid Growth and Raises Guidance
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App